Attorney Docket No. 029650-103

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of
Tetsuya ISHIKAWA et al.
Application No.: 09/934,706
Filing Date: August 23, 2001
Title: COLLAGEN-BINDING PHYSIOLOGICALLY ACTIVE POLYPEPTIDE

Group Art Unit: 1653
Examiner: Robert B. Mondesi
Confirmation No.: 9286

SECOND
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a **SECOND** Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of $180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☒ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of $180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By _____
Susan M. Dadio
Registration No. 40,373

Date: August 31, 2004

Attorney's Docket No. 029650-103

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	)	
	)	
Tetsuya ISHIKAWA et al.	)	Group Art Unit: 1653
	)	
Application No.: 09/934,706	)	Examiner: Robert B. Mondesi
	)	
Filed: August 23, 2001	)	Confirmation No.: 9286
	)	
For: COLLAGEN-BINDING PHYSIOLOGICALLY ACTIVE POLYPEPTIDE	)	

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. Also enclosed is a copy of the Supplementary European Search Report dated June 15, 2004, from the corresponding European patent application. It is noted that International Publication No. 96/394300 and the Owens et al. article which are both cited in the Supplementary European Search Report were previously identified and provided in the First Information Disclosure Statement filed August 23, 2001, and are not again being provided herewith.

Foreign Patent Document

International Publication No. WO 00/49159 A1 to ISHIKAWA, et al.,published August 24, 2000.

Non Patent Documents

José A. ANDRADES et al., "A Recombinant Human TGF-β1 Fusion Protein with Collagen-Binding Domain Promotes Migration, Growth, and Differentiation of Bone Marrow Mesenchymal Cells," Experimental Cell Research, 1999, pp. 485-498, Vol. 250, Academic Press, Orlando, FL.

Frederick L. HALL et al., "Design, expression, and renaturation of a lesion-targeted recombinant epidermal growth factor-von Willebrand factor fusion protein: Efficacy in an animal model of experimental colitis," International Journal of Molecular Medicine, 2000, pp. 635-643, Vol. 6,.D.A. Spandidos, Athens, Greece.

Tetsuya ISHIKAWA et al., "Production of a Biologically Active Epidermal Growth Factor Fusion Protein with High Collagen Affinity," J. Biochem., 2001, pp. 627-633, Vol. 129, The Japanese Biochemical Society, Tokyo, Japan.

The documents are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c), a statement is enclosed.

I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date August 31, 2004

By: _____
Susan M. Dadio
Registration No. 40,373

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Substitute for form 1449A/PTO & 1449B/PTO

SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	09/934,706
Filing Date	August 23, 2001
First Named Inventor	Tetsuya ISHIKAWA et al.
Examiner Name	Robert B. Mondesi
Attorney Docket Number	029650-103

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS - *copy enclosed						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
	00/49159	A1	WO	08-24-2000				*			

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	José A. ANDRADES et al., "A Recombinant Human TGF-β1 Fusion Protein with Collagen-Binding Domain Promotes Migration, Growth, and Differentiation of Bone Marrow Mesenchymal Cells," Experimental Cell Research, 1999, pp. 485-498, Vol. 250, Academic Press, Orlando, FL.
	Frederick L. HALL et al., "Design, expression, and renaturation of a lesion-targeted recombinant epidermal growth factor-von Willebrand factor fusion protein: Efficacy in an animal model of experimental colitis," International Journal of Molecular Medicine, 2000, pp. 635-643, Vol. 6,.D.A. Spandidos, Athens, Greece.
	Tetsuya ISHIKAWA et al., "Production of a Biologically Active Epidermal Growth Factor Fusion Protein with High Collagen Affinity," J. Biochem., 2001, pp. 627-633, Vol. 129, The Japanese Biochemical Society, Tokyo, Japan.

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.